Looks like cheaper NR should be available
Judge rules to invalidate two NR patents in win for Elysium Health
24-Sep-2021 By Stephen Daniells
US Judge Colm Connolly, United States District Court for the District of Delaware, has granted the request from Elysium Health to invalidate two Dartmouth College patents licensed by ChromaDex relating to nicotinamide riboside.
nutraingredients-usa.com/Ar...
CAFC Says ChromaDex Patent Claiming Isolated Form of Vitamin B3 Fails Under 101 Feb 13, 2023 ipwatchdog.com/2023/02/13/c...
The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision affirming a Delaware court’s grant of summary judgment for Elysium Health that the asserted claims of ChromaDex, Inc.’s patent on an isolated form of vitamin B3 are directed to unpatentable subject matter under Section 101. Judge Prost authored the opinion.
U.S. Patent No. 8,197,807 is titled “Nicotinamide riboside kinase compositions and methods for using the same.” Nicotinamide riboside (NR) is a form of vitamin B3 that is naturally present in cow’s milk. The invention covers a composition containing isolated NR that results in increased biosynthesis of the coenzyme nicotinamide adenine dinucleotide (NAD+) upon oral administration.
ChromaDex sells dietary supplements embodying the patent, which it licenses from Dartmouth College, and sued Elysium for patent infringement in 2018. Elysium moved for summary judgment that the claims were invalid under Section 101 and the district court agreed, finding that the claims were directed to a natural phenomenon, specifically, “compositions comprising isolated [NR], a naturally occurring vitamin present in cow milk.”
